Antiretroviral therapy is not curative. Given the challenges in providing lifelong therapy to a
global population of more than 35 million people living with HIV, there is intense interest in …

Advances in cell-based therapy, particularly CAR-T cell therapy, have transformed the
treatment of hematological malignancies. Although an important step forward for the field …

Targeting tumor-associated macrophages (TAMs) is a promising strategy to modify the
immunosuppressive tumor microenvironment and improve cancer immunotherapy …

Cell-based immunotherapy has become the new-generation cancer medicine, and" off-the-
shelf" cell products that can be manufactured at large scale and distributed readily to treat …

Chimeric antigen receptor (CAR)-engineered T-cell (CAR-T) therapy has demonstrated
impressive therapeutic efficacy against hematological malignancies, but multiple challenges …

Allogeneic Vγ9Vδ2 (Vδ2) T cells have emerged as attractive candidates for developing
cancer therapy due to their established safety in allogeneic contexts and inherent tumor …

Autoreactive CD4 T cells that differentiate into pathogenic Th17 cells can trigger
autoimmune diseases. Therefore, investigating the regulatory network that modulates Th17 …

Osteosarcoma (OS) is the most common primary malignant bone sarcoma mainly affecting
adolescents and young adults, which often progresses to pulmonary metastasis and leads to …

T cells demand massive energy to combat cancer; however, the metabolic regulators
controlling antitumor T cell immunity have just begun to be unveiled. When studying nutrient …

Monoamine oxidase A (MAO-A) is an enzyme best known for its function in the brain, where
it breaks down neurotransmitters and thereby influences mood and behavior. Small …